Potential pharmacologic treatments for COVID-19 patients: A review study
Student Research in Translational Medicine,
Vol. 2 No. 2 (2020),
1 Khordad 2020
,
Page 14-20
https://doi.org/10.22037/smsj.v2i2.30323
Abstract
A cluster of pneumonia cases of unknown origin was detected on December 31th which led to the discovery of coronavirus disease 2019 (COVID-19). Lungs are the primary site of involvement. SARS-COV-2, which is the causative agent, enters the alveolar cells using ACE2 as a receptor. Due to exposure of first cases to Wuhan’s animal market, a zoonotic transmission was suspected. Further studies suggested human to human transmission through contact and droplets. Symptoms vary from asymptomatic to acute respiratory distress syndrome and death. Cases are diagnosed based on clinical and laboratory findings. Currently, there is no definitive treatment or vaccine and different antiviral and other treatments are being tested as possible therapeutic agents with different mechanisms, for example, Chloroquine, hydroxychloroquine, azithromycin, favipiravir, umifenovir, ribavirin, Ivermectin, etc.
- SARS-CoV-2
- COVID-19
- pharmacology
- ARDS
- treatment
How to Cite
References
Chang L, Yan Y, Wang L. Coronavirus Disease 2019: Coronaviruses and Blood Safety. Transfusion Medicine Reviews. 2020.
Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020.
Xu YH, Dong JH, An WM, Lv XY, Yin XP, Zhang JZ, et al. Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2. The Journal of infection. 2020.
Velavan TP, Meyer CG. The COVID-19 epidemic. Tropical Medicine and International Health. 2020;25(3):278-80.
Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. International Journal of Antimicrobial Agents. 2020.
Organization WH. Corona virus statistics. 2020.
Organization WH. Pandemic state.
Zhang L, Liu Y. Potential Interventions for Novel Coronavirus in China: A Systemic Review. Journal of medical virology. 2020.
Lin L, Jiang X, Zhang Z, Huang S, Zhang Z, Fang Z, et al. Gastrointestinal symptoms of 95 cases with SARS-CoV-2 infection. Gut. 2020.
Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ (Clinical research ed). 2020;368:m606.
Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity. 2020.
Cao Q, Chen Y-C, Chen C-L, Chiu C-H. SARS-CoV-2 infection in children: Transmission dynamics and clinical characteristics. Journal of the Formosan Medical Association= Taiwan yi zhi. 2020.
Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug development research. 2020.
Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-Mediated Inflammatory Responses: From Mechanisms to Potential Therapeutic Tools. Virologica Sinica. 2020.
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. The Lancet Respiratory Medicine. 2020.
Qiao J. What are the risks of COVID-19 infection in pregnant women? The Lancet. 2020.
Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. Jama. 2020.
Song Y, Liu P, Shi XL, Chu YL, Zhang J, Xia J, et al. SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19. Gut. 2020.
Xu J, Zhao S, Teng T, Abdalla AE, Zhu W, Xie L, et al. Systematic Comparison of Two Animal-to-Human Transmitted Human Coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses. 2020;12(2).
Huang WH, Teng LC, Yeh TK, Chen YJ, Lo WJ, Wu MJ, et al. 2019 novel coronavirus disease (COVID-19) in Taiwan: Reports of two cases from Wuhan, China. Journal of Microbiology, Immunology and Infection. 2020.
Gross A, Thiemig D, Koch FW, Schwarz M, Glaser S, Albrecht T. CT appearance of severe, laboratory-proven coronavirus disease 2019 (COVID-19) in a Caucasian patient in Berlin, Germany. RoFo : Fortschritte auf dem Gebiete der Rontgenstrahlen und der Nuklearmedizin. 2020.
Sun D, Li H, Lu XX, Xiao H, Ren J, Zhang FR, et al. Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study. World journal of pediatrics : WJP. 2020.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Jama. 2020.
Liu KC, Xu P, Lv WF, Qiu XH, Yao JL, Gu JF, et al. CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity. European journal of radiology. 2020;126:108941.
Ding Q, Lu P, Fan Y, Xia Y, Liu M. The clinical characteristics of pneumonia patients co-infected with 2019 novel coronavirus and influenza virus in Wuhan, China. Journal of medical virology. 2020.
Cheng SC, Chang YC, Fan Chiang YL, Chien YC, Cheng M, Yang CH, et al. First case of Coronavirus Disease 2019 (COVID-19) pneumonia in Taiwan. Journal of the Formosan Medical Association. 2020.
Ma J, Xia P, Zhou Y, Liu Z, Zhou X, Wang J, et al. Potential effect of blood purification therapy in reducing cytokine storm as a late complication of severe COVID-19. Clinical immunology (Orlando, Fla). 2020:108408.
Katzung BG. Basic&Clinical pharmacology fourteenth Edition. 2018:833.
Jameson F, Kasper,Hauser,Longo,Loscalzo. Harrison's Principle of Internal Medicine 20th Edition. 2018:913.
Sahraei Z, Shabani M, Shokouhi S, Saffaei A. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine. International Journal of Antimicrobial Agents. 2020:105945.
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, et al. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020.
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Bioscience trends. 2020.
Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020:105949.
Yao TT, Qian JD, Zhu WY, Wang Y, Wang GQ. A Systematic Review of Lopinavir Therapy for SARS Coronavirus and MERS Coronavirus-A Possible Reference for Coronavirus Disease-19 Treatment Option. Journal of medical virology. 2020.
Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. The Journal of infection. 2020.
Lim J, Jeon S, Shin HY, Kim MJ, Seong YM, Lee WJ, et al. Case of the index patient who caused tertiary transmission of coronavirus disease 2019 in Korea: The application of lopinavir/ritonavir for the treatment of COVID-19 pneumonia monitored by quantitative RT-PCR. Journal of Korean Medical Science. 2020;35(6).
Post TW. Kaletra: UptoDate in Waltham,MA; 2020, 7 April.
Database D. Remdesivir 2020,April 14 [Available from: https://www.drugbank.ca/drugs/DB14761.
Kruse RL. Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China. F1000Research. 2020;9:72.
Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug discoveries & therapeutics. 2020;14(1):58-60.
Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends. 2020;14(1):69-71.
Columbus C, Brust KB, Arroliga AC. 2019 novel coronavirus: an emerging global threat. Baylor University Medical Center Proceedings. 2020.
Du YX, Chen XP. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clinical pharmacology and therapeutics. 2020.
DrugBank Database. Favipiravir 2020, 7 April [Available from: https://www.drugbank.ca/drugs/DB12466.
Jin Z, Du X, Xu Y, Deng Y, Liu M, Zhao Y, et al. Structure of Mpro from COVID-19 virus and discovery of its inhibitors. bioRxiv. 2020.
Junmei W. Fast Identification of Possible Drug Treatment of Coronavirus Disease -19 (COVID-19) Through Computational Drug Repurposing Study2020.
Ted W. Post. Indinavir2020,April 11.
Chang Y-C, Tung Y-A, Lee K-H, Chen T-F, Hsiao Y-C, Chang H-C, et al. Potential therapeutic agents for COVID-19 based on the analysis of protease and RNA polymerase docking. 2020.
Chen H, Zhang Z, Wang L, Huang Z, Gong F, Li X, et al. First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients. medRxiv. 2020:2020.03.22.20034041.
Chen YW, Yiu C-PB, Wong K-Y. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Research. 2020;9:129-.
Zhang L, Lin D, Kusov Y, Nian Y, Ma Q, Wang J, et al. α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment. Journal of medicinal chemistry. 2020:acs.jmedchem.9b01828.
Baumann CA, Badamchian M, Goldstein AL. Thymosin α1 antagonizes dexamethasone and CD3-induced apoptosis of CD4+CD8+ thymocytes through the activation of cAMP and protein kinase C dependent second messenger pathways1This work is supported, in part, by a grant from SciClone Pharmaceuticals, San Mateo, California, to M. Badamchian and a pre-doctoral fellowship from the Philip Morris Companies Inc. to C.A. Baumann.1. Mechanisms of Ageing and Development. 1997;94(1):85-101.
M I Joffe NRS, and A R Rabson. Lymphocyte subsets in measles. Depressed helper/inducer subpopulation reversed by in vitro treatment with levamisole and ascorbic acid. J Clin Invest. 1983;72(3):971–80.
Hemilä H. Vitamin C and SARS coronavirus. The Journal of antimicrobial chemotherapy. 2004;52:1049-50.
Nonnecke BJ, McGill JL, Ridpath JF, Sacco RE, Lippolis JD, Reinhardt TA. Acute phase response elicited by experimental bovine diarrhea virus (BVDV) infection is associated with decreased vitamin D and E status of vitamin-replete preruminant calves1. Journal of Dairy Science. 2014;97(9):5566-79.
Guillin OM, Vindry C, Ohlmann T, Chavatte L. Selenium, Selenoproteins and Viral Infection. Nutrients. 2019;11(9):2101.
Database D. Ebselen 2020,March 1 [Available from: https://www.drugbank.ca/drugs/DB12610.
Post TW. Bictegravir: UpToDate; 2020, April 12.
Database D. Bictegravir 2020,March 1 [Available from: https://www.drugbank.ca/drugs/DB11799.
Villalaín J. Membranotropic effects of arbidol, a broad anti-viral molecule, on phospholipid model membranes. The journal of physical chemistry B. 2010;114(25):8544-54.
Liu Q, Xiong H-r, Lu L, Liu Y-y, Luo F, Hou W, et al. Antiviral and anti-inflammatory activity of arbidol hydrochloride in influenza A (H1N1) virus infection. Acta Pharmacologica Sinica. 2013;34(8):1075-83.
Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2020.
Alex Z, Vladimir A, Alexander Z, Bogdan Z, Victor T, Dmitry S. B, et al. Potential COVID-2019 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches2020.
Database D. Prulifloxacin 2020,March 1 [Available from: https://www.drugbank.ca/drugs/DB11892.
Katzung BG. Basic&Clinical pharmacology fourteenth Edition2018 April 9th 2020. 833 p.
Database D. Tideglusib 2020,March 1 [Available from: https://www.drugbank.ca/drugs/DB12129.
Database d. PX-12 2020,March 1 [Available from: https://www.drugbank.ca/drugs/DB05448.
CaymanChem. TDZD-8 2020,April 12 [Available from: https://www.caymanchem.com/product/16287/tdzd-8.
Medscape. Parasite Drug Shows Early Promise Against COVID-19 in Vitro 2020,April 8 [Available from: https://www.medscape.com/viewarticle/928345.
Database D. Bepotastine. 2020,April 11.
Medical Press. Many drugs already approved by FDA may have promise against COVID-19 2020,March 24 [Available from: https://medicalxpress.com/news/2020-03-drugs-fda-covid-.html.
Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu S, et al. Management of corona virus disease-19 (COVID-19): the Zhejiang experience. Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang University Medical sciences. 2020;49(1):0.
Du Y, Tu L, Zhu P, Mu M, Wang R, Yang P, et al. Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan: A Retrospective Observational Study. American Journal of Respiratory and Critical Care Medicine.0(ja):null.
Zhang H, Huang Y, Xie C. The Treatment and Outcome of a Lung Cancer Patient Infected with SARS-CoV-2. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2020.
Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. The Lancet Infectious diseases. 2020.
Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, et al. Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest. 2020.
Keith P, Day M, Perkins L, Moyer L, Hewitt K, Wells A. A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19. Critical Care. 2020;24(1):128.
- Abstract Viewed: 530 times
- PDF Downloaded: 85 times
